Nuvalent (NUVL) Change in Acquisitions & Divestments (2022 - 2026)
Nuvalent (NUVL) reported Change in Acquisitions & Divestments of $181.5 million for Q1 2026, down 40.0% on a YoY basis from $302.6 million in Q1 2025, and up 11.31% quarter-over-quarter from $163.1 million in Q4 2025.
Nuvalent (NUVL) Change in Acquisitions & Divestments (2022 - 2026) Analysis & Trends
Nuvalent has reported Change in Acquisitions & Divestments for 5 years, with the latest figure at $181.5 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 40.0% year-over-year to $181.5 million; the trailing twelve-month figure through Mar 2026 stood at $812.6 million (up 19.9% YoY), and the FY2025 full-year result was $933.7 million, up 106.82% from the prior year.
- Change in Acquisitions & Divestments for Q1 2026 stood at $181.5 million, up from $163.1 million in the prior quarter.
- The five-year high for Change in Acquisitions & Divestments was $302.6 million in Q1 2025, with the low at $27.0 million in Q1 2022.
- Historically, Change in Acquisitions & Divestments has averaged $122.6 million across 5 years, with a median of $105.0 million in 2024.
- Annual changes were most pronounced in 2025 — Change in Acquisitions & Divestments soared 296.85% — and 2026, when it slumped 40.0%.
- Nuvalent's Change in Acquisitions & Divestments stood at $97.2 million in 2022, then climbed by 13.62% to $110.5 million in 2023, then increased by 28.96% to $142.4 million in 2024, then increased by 14.5% to $163.1 million in 2025, then rose by 11.31% to $181.5 million in 2026.
- The last three Change in Acquisitions & Divestments figures came in at $181.5 million (Q1 2026), $163.1 million (Q4 2025), and $232.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 181.55 Mn |
| Mar 31, 2026 | 181.55 Mn |
| Dec 31, 2025 | 163.10 Mn |
| Dec 31, 2025 | 163.10 Mn |
| Sep 30, 2025 | 232.44 Mn |
| Sep 30, 2025 | 232.44 Mn |
| Jun 30, 2025 | 235.55 Mn |
| Jun 30, 2025 | 235.55 Mn |
| Mar 31, 2025 | 302.59 Mn |
| Mar 31, 2025 | 302.59 Mn |
| Dec 31, 2024 | 142.45 Mn |
| Dec 31, 2024 | 142.45 Mn |
| Sep 30, 2024 | 127.71 Mn |
| Sep 30, 2024 | 127.71 Mn |
| Jun 30, 2024 | 105.04 Mn |
| Jun 30, 2024 | 105.04 Mn |
| Mar 31, 2024 | 76.25 Mn |
| Mar 31, 2024 | 76.25 Mn |
| Dec 31, 2023 | 110.46 Mn |
| Dec 31, 2023 | 110.46 Mn |